Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia

27 April 2022 - NICE has published evidence-based recommendations on the use of venetoclax in combination with low dose cytosine ...

Read more →

NICE terminates appraisal of nivolumab

20 April 2022 - This is the first appraisal of nivolumab to be terminated by NICE. ...

Read more →

Over 700 people a year could benefit from a new potentially life-extending lung cancer drug which targets a specific genetic mutation

14 April 2022 - An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced ...

Read more →

Alpelisib for patients with advanced hormone receptor positive, HER2 negative, PIK3CA mutated breast cancer

7 April 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

NICE backs Biogen’s Vumerity for multiple sclerosis

13 April 2022 - Patients with relapsing-remitting multiple sclerosis in England, Wales and Northern Ireland can now access treatment with ...

Read more →

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma

13 April 2022 - NICE has published evidence based recommendations on the use of daratumumab (Darzalex) for the treatment of ...

Read more →

Highest risk COVID-19 patients receive ‘brilliant’ new antivirals at home

9 April 2022 - Thousands of patients with COVID-19 who are most likely to be admitted to hospital are receiving ...

Read more →

NICE reaches important milestone in the UK’s efforts to tackle antimicrobial resistance

12 April 2022 - Two new antimicrobial drugs - cefiderocol and ceftazidime–avibactam - are close to becoming the first to be ...

Read more →

Upadacitinib, abrocitinib and tralokinumab for atopic dermatitis

8 April 2022 - A rare multiple technology assessment from NICE. ...

Read more →

NICE recommends Koselugo for the treatment of neurofibromatosis type 1

8 April 2022 - NICE has recommended AstraZeneca and MSD’s Koselugo (selumetinib) for use by the NHS in England, within ...

Read more →

NICE says new triple negative advanced breast cancer drug too expensive for NHS use

7 April 2022 - NICE has today issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or ...

Read more →

Hundreds of people with some forms of urothelial cancer to receive new treatment

7 April 2022 - Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new ...

Read more →

Thousands of people set to benefit from first new treatment for osteoporosis for over a decade

1 April 2022 - Thousands of people in England and Wales with severe osteoporosis who are at high risk of fracture ...

Read more →

Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm

30 March 2022 - Tagraxofusp is human interleukin-3 genetically conjugated to diphtheria toxin protein. ...

Read more →

Priorities for NICE in health and social care

23 March 2022 - Over the past two years there has been an unprecedented increase in medical research, the NHS has ...

Read more →